A method of treating lymphoma in a subject comprises administering to a subject afflicted with lymphoma an antibody that binds to tenascin in a therapeutically effective amount. Preferably the antibody is monoclonal antibody 81C6 or an antibody that binds to the epitope bound by monoclonal antibody 81C6. Preferably the antibody is labeled with or conjugated to a chemotherapeutic agent, particularly a radioisotope such as .sup.131I.
 The present invention was made with Government support under grant number NS 20023-18 from the National Institutes of Health and grant number DE-FG-05-95ER62021 from the Department of Energy. The Government has certain rights to this invention.